X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (923) 923
index medicus (844) 844
flt3 (732) 732
hematology (602) 602
oncology (556) 556
acute myeloid-leukemia (458) 458
acute myeloid leukemia (424) 424
internal tandem duplication (412) 412
mutation (404) 404
animals (385) 385
leukemia (370) 370
fms-like tyrosine kinase 3 - genetics (347) 347
female (328) 328
aml (322) 322
leukemia, myeloid, acute - genetics (305) 305
male (294) 294
mice (291) 291
cancer (275) 275
acute myelogenous leukemia (260) 260
leukemia, myeloid, acute - drug therapy (253) 253
mutations (245) 245
hemic and lymphatic diseases (228) 228
middle aged (220) 220
fms-like tyrosine kinase 3 - antagonists & inhibitors (219) 219
tyrosine (215) 215
adult (207) 207
flt3 ligand (197) 197
tyrosine kinase inhibitor (189) 189
chemotherapy (186) 186
prognosis (184) 184
aged (174) 174
cell line, tumor (174) 174
expression (173) 173
fms-like tyrosine kinase 3 - metabolism (169) 169
article (163) 163
leukemia, myeloid, acute - pathology (153) 153
protein kinase inhibitors - pharmacology (149) 149
research (148) 148
kinases (142) 142
analysis (141) 141
apoptosis (140) 140
signal transduction (131) 131
phosphorylation (127) 127
immunology (126) 126
adolescent (125) 125
antineoplastic agents - pharmacology (123) 123
genetic aspects (122) 122
sorafenib (121) 121
stem cells (121) 121
cell biology (120) 120
embryonic structures (120) 120
antineoplastic agents - therapeutic use (118) 118
hemic and immune systems (118) 118
activation (112) 112
gene expression (109) 109
cells (108) 108
gene (107) 107
leukemia, myeloid, acute - metabolism (107) 107
fms-like tyrosine kinase 3 (106) 106
myeloid leukemia (106) 106
health aspects (105) 105
biochemistry & molecular biology (104) 104
protein kinase inhibitors - therapeutic use (104) 104
hematology, oncology and palliative medicine (102) 102
in-vivo (100) 100
dendritic cells (97) 97
in-vitro (97) 97
flt3 mutations (96) 96
young adult (96) 96
proteins (95) 95
pharmacology & pharmacy (94) 94
apoptosis - drug effects (93) 93
prognostic-significance (93) 93
cell proliferation - drug effects (91) 91
constitutive activation (91) 91
treatment outcome (91) 91
protein-tyrosine kinase (90) 90
transplantation (90) 90
flow cytometry (89) 89
acute lymphoblastic-leukemia (86) 86
child (86) 86
resistance (86) 86
cell proliferation (85) 85
flt3 inhibitors (85) 85
fluids and secretions (85) 85
gene mutations (83) 83
inhibitors (83) 83
myelodysplastic syndrome (83) 83
therapy (83) 83
chemistry, medicinal (81) 81
leukemia, myeloid, acute - mortality (81) 81
signal transduction - drug effects (81) 81
tandem repeat sequences (81) 81
kinase inhibitor (80) 80
minimal residual disease (80) 80
receptor (80) 80
flt3 inhibitor (79) 79
survival (79) 79
bone marrow (78) 78
tyrosine kinase (77) 77
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Medicinal Chemistry, ISSN 0022-2623, 10/2012, Volume 55, Issue 20, pp. 8721 - 8734
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 06/2017, Volume 16, Issue 6, pp. 991 - 1001
The receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3), involved in regulating survival, proliferation, and differentiation of hematopoietic... 
AML | POTENT INHIBITOR | INTENSIVE CHEMOTHERAPY | PTK INHIBITORS | ONCOLOGY | PROMOTES RESISTANCE | RISK MYELODYSPLASTIC SYNDROME | KINASE INHIBITOR | MUTATIONS | SORAFENIB | PHASE-I | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Leukemia, Myeloid, Acute - pathology | Humans | Protein Multimerization | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Clinical Trials as Topic | Tandem Repeat Sequences | fms-Like Tyrosine Kinase 3 - chemistry | fms-Like Tyrosine Kinase 3 - metabolism | Leukemia, Myeloid, Acute - mortality | fms-Like Tyrosine Kinase 3 - genetics | Drug Resistance, Neoplasm - genetics | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Leukemia, Myeloid, Acute - drug therapy | Protein Binding | Protein Interaction Domains and Motifs | Protein Kinase Inhibitors - pharmacology | Mutation | Drug Evaluation, Preclinical | Leukemia, Myeloid, Acute - genetics | Cell proliferation | Tyrosine | Drugs | Medical research | Cell survival | Myeloid leukemia | Leukemia | Clinical trials | Kinases | Survival | Patients | Progenitor cells | Proteasome inhibitors | Hemopoiesis | Signaling | Chemotherapy | Inhibitors | Cells (biology) | Protein-tyrosine kinase receptors | Flt3 protein | Acute myeloid leukemia | Protein-tyrosine kinase | Cancer | FLT3 internal tandem duplication | FLT3 point mutation | FLT3 inhibitors | acute myeloid leukemia | resistance
Journal Article
Investigational New Drugs, ISSN 0167-6997, 10/2014, Volume 32, Issue 5, pp. 825 - 837
The G1 restriction point is critical for regulating the cell cycle and is controlled by the Rb pathway (CDK4/6-cyclin D1-Rb-p16/ink4a). This pathway is... 
Medicine & Public Health | Cell cycle | Oncology | In vivo antitumor activity | Pharmacology/Toxicology | Combination therapy | LY2835219 | Kinase inhibitor | CDK4/6 inhibitor | Cdk4/6 inhibitor | LUNG | HUMAN BREAST | PHOSPHORYLATION | CANCER | DEPENDENT KINASE 4/6 | CONSTITUTIVELY ACTIVATED FLT3 | ONCOLOGY | BRAIN METASTASES | RESTRICTION POINT | TUMOR-SUPPRESSOR | PHARMACOLOGY & PHARMACY | EXPRESSION | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Neoplasms - metabolism | Humans | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | Deoxycytidine - therapeutic use | Aminopyridines - therapeutic use | Female | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Retinoblastoma Protein - metabolism | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | Protein Kinase Inhibitors - therapeutic use | Aminopyridines - pharmacology | Retinoblastoma Protein - antagonists & inhibitors | Cell Line, Tumor | Benzimidazoles - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | G1 Phase Cell Cycle Checkpoints - drug effects | Neoplasms - pathology | Deoxycytidine - analogs & derivatives | Dosage and administration | Research | Gemcitabine | Studies | Protein expression | Inhibitor drugs | Kinases | Cancer therapies | Analysis | CDK4 | Preclinical Studies | 6 inhibitor
Journal Article
Journal Article
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2018, Volume 18, pp. S1 - S2
Journal Article
Cancer Discovery, ISSN 2159-8274, 2013, Volume 3, Issue 2, pp. 168 - 181
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 07/2019, Volume 60, Issue 8, pp. 1866 - 1876
Acute myeloid leukemia (AML) is a heterogeneous disease and remains a therapeutic challenge. Cytogenetics is a well-established prognostic factor. Recent... 
quizartinib | Acute myeloid leukemia | FLT3 inhibitors | AML | INTERNAL TANDEM DUPLICATION | ACUTE MYELOGENOUS LEUKEMIA | ACUTE MYELOID-LEUKEMIA | D835 MUTATIONS | TYROSINE KINASE INHIBITORS | CONSTITUTIVELY ACTIVATED FLT3 | ONCOLOGY | THERAPEUTIC TARGET | MEDIATED RESISTANCE | PROGNOSTIC-SIGNIFICANCE | HEMATOLOGY
Journal Article
Journal of Computer-Aided Molecular Design, ISSN 0920-654X, 4/2012, Volume 26, Issue 4, pp. 437 - 450
Journal Article
ChemMedChem, ISSN 1860-7179, 02/2017, Volume 12, Issue 3, pp. 207 - 213
Journal Article
Blood, ISSN 0006-4971, 08/2017, Volume 130, Issue 6, pp. 789 - 802
The bone marrow (BM) provides a protective microenvironment to support the survival of leukemic cells and influence their response to therapeutic agents. In... 
STEM-CELLS | MICROENVIRONMENT | FLT3 | PATHWAY | TYROSINE KINASE INHIBITOR | ACUTE MYELOID-LEUKEMIA | DRUG-RESISTANCE | HEMATOLOGY | UP-REGULATION | MUTANT FLT3-POSITIVE AML | PKC412 | Pyrazoles - therapeutic use | Stromal Cells - pathology | Humans | Leukemia, Myeloid, Acute - metabolism | STAT Transcription Factors - metabolism | Antineoplastic Agents - therapeutic use | Janus Kinase 1 - metabolism | Proto-Oncogene Proteins c-bcl-2 - metabolism | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Janus Kinase 2 - metabolism | Stromal Cells - drug effects | Leukemia, Myeloid, Acute - drug therapy | Bone Marrow Cells - drug effects | Female | Antineoplastic Agents - pharmacology | Tumor Cells, Cultured | Janus Kinase 2 - antagonists & inhibitors | Pyrazoles - pharmacology | Cell Line | Leukemia, Myeloid, Acute - pathology | Stromal Cells - metabolism | Bone Marrow Cells - pathology | Janus Kinase 1 - antagonists & inhibitors | Sulfonamides - pharmacology | Drug Synergism | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Animals | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Mice | Protein Kinase Inhibitors - pharmacology | Bone Marrow Cells - metabolism | Drug Resistance, Neoplasm - drug effects
Journal Article